Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.<div><div style="text-align: justify;"><span>Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.</span></div></div>
"Sinopsis" puede pertenecer a otra edición de este libro.
Librería: Books Puddle, New York, NY, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 26397306503
Cantidad disponible: 4 disponibles
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. Thiswill indirectly benefit the patients & the community as a whole. 80 pp. Englisch. Nº de ref. del artículo: 9786203869576
Cantidad disponible: 2 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Print on Demand. Nº de ref. del artículo: 400151896
Cantidad disponible: 4 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. PRINT ON DEMAND. Nº de ref. del artículo: 18397306509
Cantidad disponible: 4 disponibles
Librería: moluna, Greven, Alemania
Condición: New. Nº de ref. del artículo: 490541870
Cantidad disponible: Más de 20 disponibles
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
Taschenbuch. Condición: Neu. Neuware -Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.Books on Demand GmbH, Überseering 33, 22297 Hamburg 80 pp. Englisch. Nº de ref. del artículo: 9786203869576
Cantidad disponible: 2 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. Thiswill indirectly benefit the patients & the community as a whole. Nº de ref. del artículo: 9786203869576
Cantidad disponible: 1 disponibles
Librería: preigu, Osnabrück, Alemania
Taschenbuch. Condición: Neu. Extended-spectrum ¿-lactamase producing [.]: An Overview | ESBL producing [.] | Abhishek Mehta | Taschenbuch | Englisch | 2021 | LAP LAMBERT Academic Publishing | EAN 9786203869576 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu Print on Demand. Nº de ref. del artículo: 120373730
Cantidad disponible: 5 disponibles